IP Library Granted Patent US 9,884,124
Granted Patent B2
US 9,884,124 · App. 15/017,602 · Granted Feb 6, 2018

Carriers for improved drug delivery

Inventors: Tarik Soliman (Cambridge, MA); Laura M. Hales (Cambridge, MA); Howard P. Sard (Arlington, MA); Mukkanti Amere (Woburn, MA)
Assignee: Extend Biosciences, Inc.
A61K47/48215A61K38/22A61K47/551A61K47/60
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,884,124
App. No.
15/017,602
Granted
Feb 6, 2018
Kind
B2
Abstract

The invention provides carriers that enhance the absorption, half-life or bioavailability of therapeutic compounds. The carriers comprise targeting groups that bind the Vitamin D Binding protein (DBP), conjugation groups for coupling the targeting groups to the therapeutic compounds, and optionally scaffolding moieties.

Claims (15)

1. A method of treating a subject with a therapeutic peptide, comprising administering a carrier-drug conjugate comprising a targeting group comprising vitamin D that is not hydroxylated at the Carbon 1 position, wherein said targeting group is stably linked to said therapeutic peptide.

2. The method of claim 1 , wherein said therapeutic peptide is a protein having ghrelin activity comprising an amino acid sequence with at least a 90% sequence identity to SEQ ID NO:5.

3. The method of claim 1 , wherein said carrier-drug conjugate further comprises a scaffold.

4. The method of claim 1 , wherein said carrier-drug conjugate is in a pharmaceutically acceptable formulation.

5. The method of claim 1 , wherein said carrier-drug conjugate is delivered to said subject by a transdermal, oral, parenteral, subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intrasynovial, intrasternal, intrathecal, intralesional, intracranial injection, infusion, inhalation, ocular, topical, rectal, nasal, buccal, sublingual, vaginal, or implanted reservoir mode.

6. The method of claim 5 , wherein said carrier-drug conjugate is delivered to said subject by an intravenous mode.

7. The method of claim 3 , wherein said scaffold is poly(ethylene glycol).

8. The method of claim 1 , wherein said subject is a vertebrate.

9. The method of claim 8 , wherein said vertebrate is a mammal.

10. The method of claim 9 , wherein said mammal is selected from the group consisting of a primate, mouse, hamster, guinea pig, and rat.

11. The method of claim 9 , wherein said mammal is a human.

12. The method of claim 2 , wherein said subject is a vertebrate.

13. The method of claim 12 , wherein said vertebrate is a mammal.

14. The method of claim 13 , wherein said mammal is selected from the group consisting of a primate, mouse, hamster, guinea pig, and rat.

15. The method of claim 13 , wherein said mammal is a human.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 10, 2016
From: SOLIMAN, TARIK M.; HALES, LAURA M.
To: EXTEND BIOSCIENCES, INC.
Reel/Frame 038238/0323 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 10, 2016
From: SARD, HOWARD P.; AMERE, MUKKANTI
To: ORGANIX, INC.
Reel/Frame 038238/0328 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 10, 2016
From: ORGANIX, INC.
To: EXTEND BIOSCIENCES, INC.
Reel/Frame 038238/0339 →
Continuity (5)
Division 14401519
Provisional Application 61780346 · Mar 13, 2013
Provisional Application 61673874 · Jul 20, 2012
Provisional Application 61648516 · May 17, 2012
Related Publication 20160144049A1 · May 26, 2016